Efficacy of dichloroacetate as a lactate-lowering drug

Journal of Clinical Pharmacology

Volumn 43, Issue 7, 2003, Pages 683-691

  Stacpoole, Peter W ^a,b   Nagaraja, Nelamangala V ^b   Hutson, Alan D ^c  

^a Department of Clinical and Health Psychology   (United States)

^b UNIVERSITY OF FLORIDA HEALTH   (United States)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Dichloroacetate; Lactate; Lactic acidosis; Metaanalysis

Indexed keywords

ANESTHETIC AGENT; ANTIMALARIAL AGENT; CARDIOVASCULAR AGENT; DICHLOROACETIC ACID; NONOXINOL 9; PLACEBO; PYRUVATE DEHYDROGENASE;

ADULT; BURN; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIABETES MELLITUS; DOSE RESPONSE; DRUG EFFICACY; ENZYME ACTIVATION; FEMALE; HUMAN; HYPERLACTATEMIA; LACTIC ACIDOSIS; MALARIA; MALE; META ANALYSIS; PHARMACODYNAMICS; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SEPSIS;

EID: 0037636003     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270003254637     Document Type: Review

References (65)

1. Whitehouse S, Randle PJ: Activation of pyruvate dehydrogenase in perfused rat heart by dichloroacetate. Biochem J 1973;134:651-653.
2. Stacpoole PW: The pharmacology of dichloroacetate. Metabolism 1989;38:1124-1144.
3. Stacpoole PW, Barnes CL, Hurbanis MD, et al. Treatment of congenital lactic acidosis with dichloroacetate. Arch Dis Child 1997;77:535-541.
4. Bersin RM, Stacpoole PW: Dichloroacetate as metabolic therapy for myocardial ischemia and failure. Am Heart J 1997;134:841-855.
5. Gibala MJ, Saltin B: PDH activation by dichloroacetate reduces TCA cycle intermediates at rest but not during exercise in humans, Am J Physiol (Endocrinol Metab 40) 1999;277:E33-E38.
6. Timmons JA, Gustafsson T, Sundberg CJ, et al: Substrate availability limits human skeletal muscle oxidative ATP regeneration at the onset of ischemic exercise. J Clin Invest 1996;97:79-84.
7. Carraro F, Klein S, Rosenblatt JI, Wolfe RR: Effect of dichloroacetate on lactate concentration in exercising humans. J Appl Physiol 1989;66:591-597.
8. Stacpoole PW: Lactic acidosis and other mitochondrial disorders. Metabolism 1997;46:306-321.
9. Stacpoole PW, Moore GW, Kornhauser DM: Metabolic effects of dichloroacetate in patients with diabetes mellitus and hyperlipoproteinemia. N Engl J Med 1978;298:526-530.
10. Wells PG, Moore GW, Rabin D, et al: Metabolic effects and pharmacokinetics of intravenously administered dichloroacetate in humans. Diabetologia 1980;19:109-113.
11. Krishna S, Agbenyega T, Angus BJ, et al: Pharmacokinetics and pharmacodynamics of dichloroacetate in children with lactic acidosis due to severe malaria. QJ Med 1995;88:341-349.
12. Stacpoole PW, Wright EC, Baumgartner TG, et al: A controlled clinical trial of dichloroacetate for treatment in patients of lactic acidosis in adults. N Engl J Med 1992;327:1564-1569.
13. Fox AW, Sullivan BW, Buffini JD, et al: Reduction of serum lactate by sodium dichloroacetate, and human pharmacokinetic-pharmacodynamic relationships. J Pharmacol Exp Ther 1996;279: 686-693.
14. Pavlakis SG, Kingsley PB, Kaplan GP, et al: Magnetic resonance spectroscopy use in monitoring MELAS treatment. Arch Neurol 1998;55:849-852.
15. Shangraw RE, Fisher DM: Pharmacokinetics and pharmacodynamics of dichloroacetate in patients with cirrhosis. Clin Pharmacol Ther 1999;66:380-390.
16. Shangraw RE, Winter R, Hromco J, et al: Amelioration of lactic acidosis with dichloroacetate during liver transplantation in humans. Anesthesiology 1994;81:1127-1138.
17. Stacpoole PW, Harman EM, Curry SH, Baumgartner TG, Misbin RT: Treatment of patients with lactic acidosis with dichloroacetate. N Engl J Med 1983;309:390-396.
18. Stacpoole PW, Lorenz AC, Thomas RG, Harman EM: Dichloroacetate in the treatment of lactic acidosis. Ann Intern Med 1988;108:58-63.
19. Shangraw RE, Rabkin JM, Lopaschuk GD: Hepatic pyruvate dehydrogenase activity in humans: effect of cirrhosis, transplantation, and dichloroacetate. Am J Physiol (Gastrointest Liver Physiol 37) 1998;274:G569-G577.
20. Shangraw RE, Jahoor F, Wolfe RR, Lang CH: Pyruvate dehydrogenase inactivity is not responsible for sepsis-induced insulin resistance. Crit Care Med 1996;24:566-574.
21. Wargovich TJ, MacDonald RG, Hill JA, et al: Myocardial metabolic and hemodynamic effects of dichloroacetate in coronary artery disease. Am J Cardiol 1988;61:65-70.
22. Jahoor F, Shangraw RE, Miyoshi H, et al: Role of insulin and glucose oxidation in mediating the protein catabolism of burns and sepsis. Am J PhysioI (Endocrinol Metab 20) 1999;257:E323-E331.
23. Bersin RM, Wolfe C, Kwaswman M, et al: Improved hemodynamic function and mechanical efficiency in congestive heart failure with sodium dichloroacetate. J Am Coll Cardiol 1994;23:1617-1624.
24. Agbenyega T, Angus BJ, Bedu-Addo G, et al: Glucose and lactate kinetics in children with severe malaria. J Clin Endo Metab 2000;85:1569-1576.
25. Takanashi J, Sugita K, Tanabe Y, et al: Dichloroacetate treatment in Leigh syndrome caused by mitochondrial DNA mutation. J Neurol Sci 1997;145:83-86.
26. Krishna S, Supanaranond W, Pukrittayakamee S, et al: The disposition and effects of two doses of dichloroacetate in adults with severe falciparum malaria. Br J Clin Pharmacol 1996;41:29-34.
27. Krishna S, Supanaranond W, Pukrittayakamee S, et al: Dichloroacetate for lactic acidosis in severe malaria: a pharmacokinetic and pharmacodynamic assessment. Metabolism 1994;43:974-981.
28. Montague T, DeAlmeida J, Lopaschuk G, et al: Enhanced glucose oxidation in exercise-induced myocardial ischemia. Can J Cardiol 1994;10:913-919.
29. Toth PP, El-Shanti H, Elvins S, et al: Transient improvement of congenital lactic acidosis in a male infant with pyruvate decarboxylase deficiency treated with dichloroacetate. J Pediatr 1993;123:427-430.
30. Ettinger S, Gray K, Whisler S, Sinoway L: Dichloroacetate reduces sympathetic nerve responses to static exercise. Am J Physiol (Heart Circ Physiol 30) 1991;261:H1653-H1658.
31. Wolfe RR, Jahoor F, Herndon DN, Miyoshi H: Isotopic evaluation of the metabolism of pyruvate and related substrates in normal adult volunteers and severely burned children: effect of dichloroacetate and glucose infusion. Surgery 1991;111:54-67.
32. Curry SH, Henderson GH, Lorenz A, et al: Hemodialysis studies with dichloroacetate. Eur J Clin Pharmacol 1991;40:613-617.
33. Saijo T, Naito E, Ito M, et al: Therapeutic effect of sodium dichloroacetate on visual and auditory hallucinations in a patient with MELAS. Neuropediatrics 1991;22:166-167.
34. Jahoor F, Peters EJ, Wolfe RR: The relationship between gluconeogenic substrate supply and glucose production in humans. Am J Physiol 1990;258:E288-E296.
35. Ludvik B, Peer G, Cada E, Graf H: Effect of dichloroacetate and bicarbonate on hemodynamic parameters in healthy volunteers. Clin Res 1990;38:332A.
36. Robinson J, Norman MG: Feeding problems and lactic acidosis in a 10-week-old boy. Pediatr Neurosci 1989;15:28-35.
37. Naito E, Kuroda Y, Toshima K, et al: Effect of sodium dichloroacetate on human pyruvate metabolism. Brain Dev 1989;11: 195-197.
38. Wilson JR, Mancini DM, Ferraro N, Egler J: Effect of dichloroacetate on the exercise performance of patients with heart failure. J Am Coll Cardiol 1988;12:1464-1469.
39. Okabe I, Kodama H, Shimoizumi H, et al: Treatment of lactic acidosis: effects of dichloroacetate on lactate and pyruvate levels in the cerebrospinal fluid. Eur J Pediatr 1986;145:159.
40. Kuroda Y, Ito M, Toshima K, et al: Treatment of chronic congenital lactic acidosis by oral administration of dichloracetate. J Inher Metab Dis 1986;9:244-252.
41. Aynsley-Green A, Weindling AM, Soltesz G, et al: Case report: dichloroacetate in the treatment of congenital lactic acidosis. J Inher Metab Dis 1984;7:26.
42. Aynsley-Green A, Weindling AM, Soltesz G: Transient lactic acidosis and hyperalaninaemia associated with neonatal hyperinsulinaemic hypoglycaemia: the effects of dichloroacetate (DCA). Eur J Pediatr 1983;141:114-117.
43. Evans OB, Stacpoole PW: Brief treatment with dichloroacetate does not modify suspected subacute necrotizing encephalomyelitis. Ann Neurol 1980;8:647-648.
44. Curry SH, Chu P-I, Baumgartner TG, Stacpoole PW: Plasma concentrations and metabolic effects of intravenous sodium dichloroacetate. Clin Pharmacol Ther 1985;37:89-93.
45. DeVivo DC, Jackson AH, Wade C, Altmann K, et al: Dichloroacetate treatment of MELAS-associated lactic acidosis. Ann Neurol 1990;28(3):437-438.
46. Planche T, Agbenyega T, Bed-Addo G, et al: A prospective comparison of malaria with other severe diseases in African children: Prognosis and optimization of management. Clin Infect Dis, in press.
47. Curry SH, Lorenz A, Chu P-I, Limacher M, Stacpoole PW: Disposition and pharmacodynamics of dichloroacetate (DCA) and oxalate following oral DCA doses. Biopharm Drug Disp 1991;12:375-390.
48. Ammini CV, Stacpoole PW: Pharmacogenomics, biotransformation and toxicology of dichloroacetate, in: Hutzinger O (ed.), The Handbook of Environmental Chemistry. Heidelberg, Germany: Springer-Verlag, 2002.
49. Cornett R, James MO, Henderson GN, et al: Inhibition of glutathione S-transferase and tyrosine metabolism by dichloroacetate: a potential unifying mechanism for its altered biotransformation and toxicity. Biochem Biophys Res Commun 1999;262:752-756.
50. Evans OB, Stacpoole PW: Prolonged hypolactatemia and increased total pyruvate dehydrogenase activity by dichloroacetate. Biochem Pharmacol 1982;31:1295-1300.
51. Morten KJ, Caky M, Matthews PM: Stabilization of the pyruvate dehydrogenase E1alpha subunit by dichloroacetate. Neurology 1998;51:1331-1335.
52. Morten KJ, Beattie P, Brown GK, Matthews PM: Dichloroacetate stabilizes the mutant E1alpha subunit in pyruvate dehydrogenase deficiency. Neurology 1999;53:612-616.
53. Jackson VN, Halestrap AP: The kinetics, substrate, and inhibitor specificity of the monocarboxylate (lactate) transporter of rat liver cells determined using the fluorescent intracellular pH indicator, 2′,7′-bis(carboxyethyl)-5(6)-carboxyfluorescein. J Biol Chem 1996; 271:861-868.
54. Shangraw RE, Fisher DM: Pharmacokinetics of dichloroacetate in patients undergoing liver transplantation. Anesthesiology 1996;84:851-858.
55. James MO, Cornett R, Yan Z, Henderson GN, Stacpoole PW: Glutathione-dependent conversion to glyoxylate, a major pathway of dichloroacetate biotransformation in hepatic cytosol from humans and rats, is reduced in dichloroacetate-treated rats. Drug Metab Dispos 1997;25:1223-1227.
56. Shangraw RE, Fisher DM: Pharmacokinetics and pharmacodynamics of dichloroacetate in patients with cirrhosis. Clin Pharmacol Ther 1999;66:380-390.
57. Shangraw RE, Rakkin JM, Lopaschuk GD: Hepatic pyruvate dehydrogenase activity in humans: effect of cirrhosis, transplantation, and dichloroacetate. Am J Physiol 1998;274:G569-G577.
58. Sugden MC, Holness MJ: Recent advances in mechanism regulating glucose oxidation at the level of the pyruvate dehydrogenase complex by PDKs. Am J Endocrinol Metab 2003;284:E855-E862.
59. Smith I, Kumar P, Molloy S, et al: Base excess and lactate as prognostic indicators for patients admitted to intensive care. Intensive Care Med 2001;27:73-82.
60. Agbenyega T, Angus BJ, Bedu-Addo G, Baffoe-Bonnie B, Guyton T, Stacpoole PW, et al: Glucose and lactate kinetics in children with severe malaria. J Clin Endocrinol Metab 2000;85:1569-1576.
61. Forsythe SM, Schmidt GA: Sodium bicarbonate for the treatment of lactic acidosis. Chest 2000;117:260-267.
62. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, et al: Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2002;345:1368-1377.
63. Stacpoole PW: Lactic acidosis. Endocr Clin North Am 1993;22:221-245.
64. Agbenyega T, Planche T, Bedu-Addo G, Ansong D, Owusu-Ofori A, Bhattaram VA, et al: Population kinetics, efficacy, and safety of dichloroacetate for lactic acidosis due to severe malaria in children. J Clin Pharmacol 2003;43:386-398.
65. Stacpoole PW, Henderson GN, Yan Z, Cornett R, James MO: Pharmacokinetics, metabolism and toxicology of dichloroacetate. Drug Metab Rev 1998;30:499-539.